Detalhe da pesquisa
1.
Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models.
Proc Natl Acad Sci U S A
; 114(40): 10713-10718, 2017 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28893978
2.
Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS".
Ann Neurol
; 91(5): 735-736, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35233827
3.
Long-term evolution of multiple sclerosis disability in the treatment era.
Ann Neurol
; 80(4): 499-510, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27464262
4.
Precision medicine in chronic disease management: The multiple sclerosis BioScreen.
Ann Neurol
; 76(5): 633-42, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25263997
5.
Disease-modifying therapies alter gut microbial composition in MS.
Neurol Neuroimmunol Neuroinflamm
; 6(1): e517, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30568995
6.
Advanced Symptom Management in Multiple Sclerosis.
Neurol Clin
; 36(1): 197-218, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29157400
7.
Clinic to in-home telemedicine reduces barriers to care for patients with MS or other neuroimmunologic conditions.
Neurol Neuroimmunol Neuroinflamm
; 5(6): e505, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30775409
8.
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
JAMA Neurol
; 73(7): 790-4, 2016 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27135594
9.
Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.
Neurol Neuroimmunol Neuroinflamm
; 2(3): e76, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25738172
10.
Switching multiple sclerosis patients with breakthrough disease to second-line therapy.
PLoS One
; 6(2): e16664, 2011 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-21304907
11.
Sex differences in multiple sclerosis.
Continuum (Minneap Minn)
; 16(5 Multiple Sclerosis): 193-210, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22810606